Topline Safety and Efficacy Data Analysis of Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA<sup>™</sup>

Nicholas Johnson<sup>1</sup>, John Day<sup>2</sup>, Johanna Hamel<sup>3</sup>, Charles Thornton<sup>3</sup>, S.H. Subramony<sup>4</sup>, Payam Soltanzadeh<sup>5</sup>, Jeffrey Statland<sup>6</sup>, Matthew Wicklund<sup>7</sup>, W. David Arnold<sup>8</sup>, Miriam Freimer<sup>8</sup>, Carrie Heusner<sup>9</sup>, Chao-Yin Chen<sup>9</sup>, Brad McEvoy<sup>9</sup>, Yiming Zhu<sup>9</sup>, Li-Jung Tai<sup>9</sup>, Elizabeth Ackermann<sup>9</sup>


<sup>1</sup>Virginia Commonwealth University, <sup>2</sup>Stanford University Medical Center, <sup>3</sup>University of Rochester, <sup>4</sup>University of Florida, <sup>5</sup>University of California, Los Angeles, <sup>6</sup>University of Kansas Medical Center, <sup>7</sup>University of Colorado, Denver, <sup>8</sup>The Ohio State University, <sup>9</sup>Avidity Biosciences



- Dr. Johnson has received personal compensation for serving as a consultant for Arthex Biotech, Avidity Biosciences, Dyne Therapeutics, Juvena Therapeutics, Kate Therapeutics, Pepgen, Rgenta Therapeutics, Sarepta Therapeutics, Takeda Pharmaceuticals, and Vertex Pharmaceuticals
- He has received personal compensation for serving on data safety monitoring board for Biogen
- He has stock or an ownership in Juvena Therapeutics
- He has received research support paid to his institution from AMO Pharma, AveXis, Dyne Therapeutics, Fulcrum Therapeutics, ML Bio, Novartis, Pepgen, Sarepta Therapeutics, Sanofi, Takeda Pharmaceuticals, and Vertex Pharmaceuticals



## The Underlying Mechanism of DM1 is Well Suited to an siRNA Approach Using an Antibody Oligonucleotide Conjugate (AOC)



- DM1 is caused by the mutant DMPK mRNA with CUG expansion sequestering CUG binding proteins which leads to mis-splicing of downstream genes<sup>1,2</sup>
- Decreasing the amount of mutant *DMPK* mRNA has the potential to free up the CUG binding proteins and reverse mis-splicing<sup>3</sup>

AOC 1001 includes<sup>4</sup>:


- **Antibody:** human TfR1-targeting, effector function-null, humanized IgG1 antibody (TfR1 mAb)
- Non-cleavable linker
- Oligonucleotide: double-stranded siRNA
  oligonucleotide complementary to both wild-type and
  mutant *DMPK* mRNA

AOC, antibody oligonucleotide conjugate; DM1, myotonic dystrophy type 1; DMPK, DM1 protein kinase; IgG, immunoglobulin G; mAb, monoclonal antibody; MBNL, muscleblind-like RNA-binding protein; mRNA, messenger ribonucleic acid; siRNA, small inhibitory ribonucleic acid; TfR1, transferrin receptor 1.

1. Brook JD, et al. *Cell.* 1992;68(4):799-808; 2. Lin X, et al. *Hum Mol Genet.* 2006;15(13):2087-2097; 3. Lee JE, Cooper TA. *Biochem Soc Trans.* 2009;37(Pt 6):1281-1286; 4. Johnson N. A Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1 (DM1): MARINA<sup>™</sup> Study Design. Poster presented at Muscular Dystrophy Association Clinical & Scientific Conference, Nashville, TN; March 13-15, 2022.



## **MARINA™** Trial Designed to Evaluate Safety and Tolerability of AOC 1001\*



- One participant receiving 4 mg/kg AOC 1001 discontinued treatment due to SAE
- All eligible participants (N=37) have enrolled in the MARINA-OLE™

AVIDITY BIOSCIENCES BIOSCIENCES BIOSCIENCES ADDITION BIOSCIENCES BIOSCIENCES

## **Generally Favorable Safety and Tolerability**



#### **Summary of Treatment Emergent Adverse Events**

	MARINA				MARINA- OLE
Subjects with ≥ 1 AE n (%)	Placebo N=10	1 mg/kg N=6	2 mg/kg N=9	4 mg/kg N=13	Total N=37
Any AE	8 (80%)	6 (100%)	9 (100%)	13 (100%)	30 (81%)
AE related to study drug	2 (20%)	1 (17%)	3 (33%)	10 (77%)	7 (19%)
Serious AE (SAE)*	0	0	1 (11%)	1 (8%)	1 (3%) <sup>‡</sup>
SAE related to study drug	0	0	0	1 (8%)	0
AE leading to study discontinuation*	0	0	0	1 (8%)	0
AE leading to death	0	0	0	0	0

10 participants treated with placebo in MARINA were newly treated with AOC 1001 in MARINA-OLE

Over 200 infusions of AOC 1001 totaling 46.2 patientyears of exposure<sup>#</sup>

Most treatment emergent adverse events (AEs) were mild or moderate  $^{\rm \dagger}$ 

- MARINA: Most common AEs
  - procedural pain (36%), anemia<sup>†</sup> (32%), COVID-19 (23%), headache (23%), nausea (23%)
  - 1 discontinuation due to an SAE
- MARINA-OLE: Most common AEs
  - Procedural pain (22%)
  - Pain in extremity and headache (16%)
  - No discontinuations



\*1 SAE considered related to AOC 1001 4 mg/kg: resulted in a partial clinical hold & patient discontinuing from treatment; 1 SAE considered unrelated to treatment: reaction to opioid pain medication after an elective surgery

<sup>‡</sup>2 SAEs in same patient, considered unrelated to treatment (cholelithiasis which resulted in pancreatitis; resolved by cholecystectomy) <sup>#</sup>As of August 2023

<sup>†</sup>Anemia was asymptomatic except for 1 participant who did not require medical intervention

### **Update on FDA Partial Clinical Hold on AOC 1001**



- In September 2022, the FDA placed a partial clinical hold on new participant enrollment in the MARINA<sup>™</sup> study in response to a serious adverse event reported in a single participant in the 4 mg/kg cohort comprising bilateral ischemia in the region of the lateral geniculate nuclei in the thalamus with subsequent hemorrhagic transformation. This was described as thalamic hemorrhage
- Comprehensive investigation by Avidity found no plausible biological link to any component of AOC 1001, the AOC platform, the transferrin receptor delivery mechanism or reduction of DMPK
- In May 2023, partial hold was eased to allow enrollment of new participants at the 2 mg/kg dose and to dose escalate 12 participants from 2 mg/kg to 4 mg/kg




### **Participants Treated With AOC 1001 Demonstrated Improvements in Myotonia and Hand Strength**


Video Hand Opening Time (vHOT)\*


Days







**Improvement** 







**Hand Grip** 



‡

1111

D183


## **AOC 1001 Demonstrates Myotonia Reduction Across 4 mg/kg Cohort**\*



vHOT is measuring hand flexor myotonia and hand extensor muscle strength

**Participant from** 4 mg/kg Multidose **Baseline vHOT** 


Day 183 vHOT 12 weeks after third dose



Improvement visible 12 weeks following the third dose at 4 mg/kg



## Improvements in Strength Measured by Quantitative Muscle Testing (QMT) Total and Manual Muscle Testing (MMT) Composite Scores MARINA<sup>™</sup>



Error bars = standard error of the mean.

\*QMT Total Score is based on 6 muscle groups from both upper and lower body: Ankle dorsiflexion, hand grip, elbow flexion, elbow extension, knee flexion, knee extension





<sup>†</sup>Placebo group combined from Cohort B1 (2 mg/kg) and Cohort B2 (4 mg/kg).

<sup>‡</sup>Post hoc statistical analysis show p<0.05 for Cohort B2 (4 mg/kg)

MMT, manual muscle testing; QMT, quantitative muscle testing.

## Consistent with Improvement in Total QMT Score, Improvements also Demonstrated in Both Upper and Lower Extremities MARINA<sup>™</sup>





## Directional Improvements Were Observed in Functional & Patient Reported Measures: 10-Meter Walk Run Test (10mWRT), Timed Up and Go (TUG), and the DM1-Activ Patient Reported Outcome (PRO)



TUG 10mWRT **DM1-Activ** (sec) 0.5-Change from Baseline (score) Change from Baseline (sec) 0.5-5-**Change from Baseline** mprovement Improvement 0.0 0.0 -5 -0.5-·10 -1.0--0.5-D183 D92 **D1** D43 D92 D183 D1 D43 D183 **D1** D92 D43 Days Days Days

→ Placebo (N=8)<sup>†</sup>
 → 2 mg/kg (N=9)
 → 4 mg/kg (N=12)
 ▲ Dosing

**Improvement** 

Frror bars = standard error of the mean.
 <sup>†</sup>Placebo group combined from Cohort B1 (2 mg/kg) and Cohort B2 (4 mg/kg).
 10mWRT, 10-meter walk run test; TUG, timed up and go test; DM1-ACTIV patient reported outcome

11

# MARINA<sup>™</sup> Phase 1/2 Trial Demonstrates AOC 1001 Impacts Disease Mechanism and Demonstrates Functional Improvement



- AOC 1001 consistently demonstrated directional improvement across multiple aspects of DM1 including measures of myotonia, strength, function and patient reported outcome
- MARINA<sup>™</sup> trial concluded with 38 participants enrolled and treated with study drug
  - All 37 participants that completed MARINA<sup>™</sup> have rolled into the MARINA-OLE<sup>™</sup> at 2-4 mg/kg of AOC 1001 and remain ongoing
- Generally favorable safety and tolerability profile
  - ~46 total patient years of exposure accumulated with over 200 doses of AOC 1001 administered\*
- Discussions with the FDA on resolving the partial clinical hold are ongoing
- Based on the solid data package from MARINA<sup>™</sup>, Avidity is now finalizing the AOC 1001 pivotal dose and Phase 3 design
- First look at data from the MARINA-OLE<sup>™</sup> study in the first-half of 2024

Y<sup>\*</sup> \*As of August 2023, and based on 38 participants treated with AOC 1001 in MARINA™ and/or MARINA-OLE™. FDA, US Food and Drug Administration.